Evidence map›Paper›PMID 33546432›Full record

ReviewCancers2021

Clinical Progress in Proton Radiotherapy: Biological Unknowns.

Laura Vanderwaeren, Rüveyda Dok, Kevin Verstrepen, Sandra Nuyts

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Technical Considerations on Proton Therapy in NRG's Multi-Institutional Clinical Trials.International journal of radiation oncology, biology, physics · 2026
    Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. NRG Oncology White Paper on the Relative Biological Effectiveness in Proton Therapy.International journal of radiation oncology, biology, physics · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Clinical and translational radiation oncology · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Laura VanderwaerenLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-8393-3863
Rüveyda DokLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
Kevin VerstrepenLaboratory of Genetics and Genomics, Centre for Microbial and Plant Genetics, KU Leuven, 3000 Leuven, Belgium.
Sandra NuytsLaboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-5540-4796
KU Leuven · BEVIB-KU Leuven Center for Microbiology · BE

Funding

Kom op tegen Kanker NAKU Leuven C24/17/703
6 · The paper itself

Abstract

Clinical use of proton radiation has massively increased over the past years. The main reason for this is the beneficial depth-dose distribution of protons that allows to reduce toxicity to normal tissues surrounding the tumor. Despite the experience in the clinical use of protons, the radiobiology after proton irradiation compared to photon irradiation remains to be completely elucidated. Proton radiation may lead to differential damages and activation of biological processes. Here, we will review the current knowledge of proton radiobiology in terms of induction of reactive oxygen species, hypoxia, DNA damage response, as well as cell death after proton irradiation and radioresistance.

Indexed as

proton radiationradiobiologyradiotherapy

Identifiers

PMID33546432
PMCPMC7913745
OpenAlexW3128887432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.